Regulation of dual-use biotechnology research control germany

1. Introduction

Dual-use biotechnology research control in Germany refers to the legal and institutional framework governing scientific research, biological materials, technologies, and technical knowledge that may have both peaceful and potentially harmful applications.

Dual-use biotechnology has significant importance in pharmaceutical research, vaccine development, genetic engineering, synthetic biology, industrial fermentation, agricultural biotechnology, and infectious disease research.

For example, biotechnology research may contribute to the development of vaccines, diagnostic technologies, antimicrobial treatments, and industrial enzymes. However, certain biological technologies may also create risks if misused for prohibited biological weapons activities or other harmful purposes.

Germany regulates dual-use biotechnology through national legislation, European Union export control regulations, international biological security obligations, criminal law, and institutional research governance.

The principal objective is to promote legitimate scientific research while preventing the unauthorised transfer, misuse, or weaponisation of biological materials, technologies, and knowledge.

Germany does not rely on a single comprehensive dual-use biotechnology research statute. Instead, its regulatory framework combines several legal instruments, particularly the EU Dual-Use Regulation, the War Weapons Control Act, the Foreign Trade and Payments Act, the Foreign Trade and Payments Ordinance, and the Biological Weapons Convention.

2. European Union Dual-Use Regulation (Regulation 2021/821)

The EU Dual-Use Regulation (Regulation (EU) 2021/821) is the principal legal instrument governing the export, transfer, brokering, and transit of specified dual-use items and technologies.

It establishes a common European export control framework for products and technologies that may have both civilian and military applications.

In biotechnology, the Regulation is relevant to specified biological materials, pathogens, toxins, equipment, and associated technologies included in its control lists.

Article 3 establishes the general requirement for export authorisation concerning items listed in Annex I.

Article 4 provides additional controls in specified circumstances involving items not listed in Annex I but intended for certain prohibited military or weapons-related end uses.

Article 5 introduces controls relating to certain cyber-surveillance items, while Article 9 permits Member States to impose additional national controls in specified circumstances.

Important compliance requirements include:

Classification of biotechnology products against applicable control lists.

Verification of export destinations and end users.

Assessment of intended end uses.

Obtaining required export authorisations.

Maintaining appropriate export documentation.

Monitoring relevant sanctions and restrictions.

The Regulation is particularly important for German biotechnology companies exporting controlled biological materials, specialised equipment, or related technology outside the European Union.

3. German Foreign Trade and Payments Act (AWG)

The Foreign Trade and Payments Act (Außenwirtschaftsgesetz – AWG) establishes Germany's national legal framework for controlling foreign trade and international economic transactions.

It supplements the EU Dual-Use Regulation and provides the legal basis for German export control enforcement.

The Act enables restrictions and controls concerning transactions that may affect Germany's security interests, international obligations, and foreign policy objectives.

Section 18 establishes criminal penalties for specified violations of foreign trade restrictions.

Section 19 provides penalties for certain administrative infringements.

Biotechnology businesses and research institutions must therefore ensure that international transfers of controlled biological materials and technologies comply with applicable export control requirements.

The AWG is particularly relevant where biotechnology exports may contribute to prohibited biological weapons programmes or other restricted military applications.

4. Foreign Trade and Payments Ordinance (AWV)

The Foreign Trade and Payments Ordinance (Außenwirtschaftsverordnung – AWV) supplements the AWG by establishing detailed administrative and regulatory requirements.

It provides additional rules concerning export restrictions, reporting obligations, licensing procedures, and controlled transactions.

The Federal Office for Economic Affairs and Export Control (Bundesamt für Wirtschaft und Ausfuhrkontrolle – BAFA) administers important aspects of Germany's export control system.

For biotechnology companies, compliance may involve:

Determining whether biological materials are controlled.

Checking applicable export control classifications.

Identifying relevant licensing requirements.

Assessing the recipient and destination.

Maintaining appropriate records.

Obtaining regulatory authorisation before controlled exports.

Not every biotechnology research material is subject to export licensing. The relevant classification depends on the technical characteristics and applicable legal control lists.

5. Biological Weapons Convention and German Legal Obligations

Germany is a State Party to the Biological Weapons Convention (BWC).

The Convention prohibits the development, production, stockpiling, acquisition, and retention of biological agents and toxins of types and quantities that have no justification for prophylactic, protective, or other peaceful purposes.

Article I establishes the fundamental prohibition.

Article III prohibits transferring biological weapons, agents, toxins, and associated equipment to recipients in prohibited circumstances.

Article IV requires States Parties to adopt necessary national measures to prohibit and prevent prohibited activities within their jurisdiction.

The Convention is particularly important for dual-use biotechnology because it distinguishes legitimate scientific and medical research from activities intended for biological weapons purposes.

Germany implements relevant prohibitions through its national criminal and weapons-control legislation.

6. War Weapons Control Act (Kriegswaffenkontrollgesetz)

The War Weapons Control Act (Kriegswaffenkontrollgesetz – KrWaffKontrG) establishes strict controls over the manufacture, acquisition, possession, and transfer of weapons classified as war weapons under German law.

The legislation is relevant to biotechnology where biological weapons-related activities fall within the applicable statutory prohibitions.

Germany's obligations under the Biological Weapons Convention are reinforced by national criminal legislation.

The Act must be considered alongside the Criminal Code and foreign trade legislation when biological materials or technologies are connected with prohibited weapons activities.

Its principal objectives include:

Preventing the development and production of prohibited weapons.

Controlling relevant weapons-related transfers.

Protecting national and international security.

Enforcing Germany's international disarmament obligations.

Ordinary biotechnology research is not automatically classified as weapons development. Its legal assessment depends on the purpose, nature, and circumstances of the activity.

7. Criminal Code and Biological Weapons Misuse

The German Criminal Code (Strafgesetzbuch – StGB) establishes criminal liability for conduct involving prohibited biological weapons activities.

Section 328 addresses unlawful handling of radioactive substances and other dangerous goods, including certain regulated materials.

Section 314 addresses particularly serious public danger through poisoning, while other criminal provisions may apply depending on the nature of the conduct.

The German legislation must also be interpreted alongside the Biological Weapons Convention and applicable international obligations.

Research institutions and biotechnology companies must ensure that their activities do not facilitate prohibited biological weapons development, production, or acquisition.

Criminal liability may arise where the statutory elements of an offence are satisfied, including the necessary intent or other applicable mental element.

8. German Genetic Engineering Act (Gentechnikgesetz)

The Genetic Engineering Act (Gentechnikgesetz – GenTG) regulates activities involving genetically modified organisms.

It is particularly relevant to dual-use biotechnology research involving engineered microorganisms, genetically modified cell systems, and other biological materials.

The legislation establishes requirements concerning:

Risk assessment of genetic engineering activities.

Safety classification of research facilities.

Containment of genetically modified organisms.

Regulatory notification and authorisation.

Prevention of unintended environmental release.

Supervision of genetic engineering activities.

The Genetic Engineering Safety Ordinance (GenTSV) supplements the Act by establishing technical and organisational safety requirements.

These provisions help ensure that legitimate biotechnology research is conducted under appropriate biological safety conditions.

However, compliance with the GenTG does not automatically satisfy separate export control or biological weapons requirements.

9. Dual-Use Research of Concern (DURC)

Dual-Use Research of Concern (DURC) refers to scientific research that is intended for legitimate purposes but may produce knowledge, materials, or technologies that could be misused in ways creating significant risks to public health, agriculture, or national security.

Examples of relevant research areas include vaccine development, pathogen research, synthetic biology, and genetic engineering.

Germany addresses such concerns through a combination of statutory controls and institutional research governance.

Research institutions may assess:

Scientific objectives and potential applications.

Biological safety implications.

Possible misuse of research findings.

Ethical considerations.

Security implications of publication and technology transfer.

Appropriate institutional oversight.

The German Research Foundation (DFG) promotes responsible research through its Code of Conduct, Guidelines for Safeguarding Good Research Practice.

Institutional review and responsible research practices complement binding legal obligations. They should not be treated as a universal statutory licensing requirement for every DURC project.

10. International Research Collaboration and Technology Transfer

International biotechnology collaboration creates additional legal responsibilities when controlled biological materials, equipment, software, or technical knowledge are transferred across borders.

German universities, pharmaceutical companies, and biotechnology research institutions frequently collaborate with international research organisations.

Such cooperation may involve sharing biological materials, research data, technical documentation, and specialised equipment.

Under Regulation (EU) 2021/821, certain controlled technologies and transfers require export authorisation.

Companies and research institutions must distinguish between:

Transfers of physical biological materials.

Transfers of controlled technical information.

Transfers of specialised biotechnology equipment.

Publication of scientific research.

International research cooperation.

Not every scientific publication or academic exchange requires an export licence. The legal position depends on the applicable definition of controlled technology, exclusions, and relevant transfer circumstances.

11. Regulatory Authorities and Enforcement

Germany maintains several institutions responsible for implementing and supervising dual-use biotechnology controls.

The authorities may investigate suspected violations, examine export transactions, impose administrative sanctions, and refer suspected criminal offences for prosecution.

Depending on the violation, consequences may include:

Administrative fines.

Criminal penalties.

Export licence suspension or refusal.

Confiscation of controlled materials.

Restrictions on international transfers.

Institutional and corporate liability where statutory requirements are met.

12. Important Judicial Decisions and Case Laws

German and European judicial decisions provide important guidance on export controls, public security, biological research, and the interpretation of dual-use restrictions.

A. CJEU, Case C-83/94, Leifer and Others (1995)

This judgment concerned German export restrictions on goods that could have both civilian and military applications.

The Court considered the relationship between restrictions on exports and the protection of public security under European Community law.

It recognised that export restrictions may be justified on public security grounds in appropriate circumstances, subject to the applicable EU legal requirements.

Relevance to biotechnology: The decision provides an important legal foundation for understanding how Germany may restrict exports of certain dual-use biotechnology products when legitimate security concerns arise.

B. CJEU, Case C-70/94, Fritz Werner Industrie-Ausrüstungen GmbH v Germany (1995)

This case concerned the export of industrial equipment and the application of German export authorisation requirements.

The Court examined the relationship between national export controls and the European Community's common commercial policy.

Relevance to biotechnology: The judgment illustrates the importance of balancing national security interests with European rules governing international trade. Its principles are relevant by analogy to controlled biotechnology equipment and materials.

C. CJEU, Case C-72/11, Afrasiabi and Others (2011)

This judgment concerned restrictive measures relating to Iran and the interpretation of prohibitions involving the supply of equipment and services that could contribute to prohibited activities.

The Court examined the meaning of prohibited circumvention and the scope of relevant restrictive measures.

Relevance to biotechnology: It demonstrates that international security restrictions must be interpreted carefully and that transactions involving potentially sensitive goods and technologies may attract legal scrutiny even where intermediaries are involved.

D. CJEU, Case C-528/16, Confédération paysanne and Others (2018)

The Court examined whether organisms obtained through newer mutagenesis techniques fall within the scope of the EU GMO Directive.

It held that organisms obtained through newer techniques generally fall within the Directive unless an applicable exemption applies.

Relevance to biotechnology: This decision is important because dual-use research may involve genetic engineering technologies. It demonstrates that scientific innovation does not automatically exempt resulting organisms from existing regulatory requirements.

E. CJEU, Case C-311/18, Data Protection Commissioner v Facebook Ireland and Maximillian Schrems (2020)

This judgment addressed international transfers of personal data and the requirements of the GDPR.

Relevance to biotechnology: International biotechnology research collaborations may involve personal genetic information, clinical research records, and identifiable participant data. The judgment reinforces the need for lawful international data transfers and appropriate privacy safeguards.

Legal qualification: These decisions do not establish a specific universal German DURC screening obligation. The Leifer and Fritz Werner judgments are particularly relevant to export control principles, while the remaining cases address related security, GMO, and data protection issues.

13. Conclusion

Germany's dual-use biotechnology research control framework combines European export control legislation, national foreign trade restrictions, genetic engineering regulations, criminal law, and international biological security obligations.

Regulation (EU) 2021/821 provides the central framework for controlling specified dual-use goods and technologies, while the Foreign Trade and Payments Act and Foreign Trade and Payments Ordinance establish important national enforcement mechanisms.

The Biological Weapons Convention provides the international foundation for preventing prohibited biological weapons activities.

Judicial decisions such as Leifer and Others (C-83/94) and Fritz Werner (C-70/94) demonstrate the importance of balancing international trade, scientific development, and national security.

Ultimately, Germany's regulatory approach seeks to protect legitimate biotechnology research while preventing the misuse of scientific knowledge, biological materials, and advanced technologies for prohibited purposes.